Breaking News

Neurotrope Announces Publication of Phase 2 Alzheimer’s Study

The multidose, exploratory trial was to evaluate Bryostatin-1 as a treatment of cognitive deficits in moderate to severe Alzheimer's disease

Neurotrope Inc. announced that data from its Phase 2, multidose, exploratory trial evaluating Bryostatin-1 as a treatment of cognitive deficits in moderate to severe Alzheimer’s disease were published online in the Journal of Alzheimer’s Disease.    The double-blind, placebo-controlled, Phase 2 trial, which was completed in May 2017, randomized patients 1:1:1 into 20 μg Bryostatin-1, 40 μg Bryostatin-1, and placebo arms. This peer-reviewed article provides what we...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters